Eli Lilly Cannabis Sativa Tincture No.17

Current evidence suggests that systemic administration of
cannabis or cannabinoids related to ?9 THC will not have a major role in mainstream pain management, but may find a niche role in certain pain states where current therapy is unsatisfactory (e.g. neuropathic pain). Modern pain treatment often utilizes multimodal analgesia allowing a reduced concentration of individual drugs and the evidence of a synergism with co-administration of a cannabinoid and an ยต-opioid agonist may provide an approach to reduce the side-effect profile. The rapidly expanding knowledge of the endocannabinoid system may lead to exciting novel
therapies that manipulate levels of endogenous cannabinoids
(e.g. FAAH breakdown inhibitors or PEA entourage-like compounds). Other avenues may explore the delivery of cannabinoids intrathecally or peripherally to target areas of analgesic action without the central effects. CB2 receptor agonists are efficacious in various animal models, including neuropathic pain without apparent central nervous system side effects and are hopeful targets for future novel analgesic agents.

From the "Future Directions" section of the 2003 British Journal of Anaesthesia article Cannabinoids and pain

For More Information About Cannabis Tinctures and to Check Out Some of Eli Lilly's Cannabis Sativa Tincture No.17's Competition

Images from Antique Cannabis Book CD, Cannabis Tinctures from Chapter 4 (image similar to, but not the same as on website).

Eli Lilly Cannabis Sativa Tincture No.17